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NKp44 subset NCR expression was decreased day 10 versu 2 in
ABCY (15.2  0.7 vs 27.2  0.7%, P  .001). CD3/16/56 dim
NKp46 expression was decreased following day 10 versus 2 (8.5 
0.2 vs 23.5  1.2 %, P  .001). Granzyme B was increased from
day 2 to 10 (25.8 1.8 vs 45.1 1.7%, P .0001) yet perforin was
decreased in ABCY day 10 versus 2 (55.7  1.8 vs 84.3  1.3%,
P  .001). ABCY CB NK and LAK cytotoxicity was increased day
10 versus 2 (NK: 71.5  1.6 vs 53.8  10.3%, P  .001; LAK:
63.2  0.24 vs 31.8  1.8%, P  .001). In summary, CB MNC
may be thawed at UCBT, CT at a later date, EvE and activated for
7–10 days to yield viable NK subsets. ABCY 10 day EvE CB
yielded increased NK KAR (CD56dim/bright) and granzyme B
expression but decreased NK C-lectin CD94/NKG2D, NCR
NKp44 and NKp46, and perforin expression.
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LANTCET: NOVEL LASER NANOTECHNOLOGY FOR GRAFT PURGING
Lapotko, D.1, Aleinikova, O.2, Lukianova, E.1, Shman, T.2,
Savitcky, V.2, Oraevsky, A.3 1. Luikov Heat and Mass Transfer Insti-
tute, Minsk, Belarus; 2. State Pediatric Center for Oncology and He-
matology, Minsk, Belarus; 3. Fairway Medical Technologies, Inc, Hous-
ton, TX.
We introduce a novel ex vivo method, Laser-Activated Nano-
Thermolysis Cell Elimination Technology (LANTCET), for
selective killing of individual tumor cells in bone marrow and
peripheral blood samples. LANTCET assumes cell-speciﬁc de-
livery of gold nanoparticles (GNP) into tumor cells and irradi-
ation of cell sample with laser pulse. Nanoparticles absorb laser
pulse, instantly heat, and produce micro-bubbles of vapor that
damages cells. This process is toxic-free, takes microseconds,
and is localized in individual cells, thus being safe for surround-
ing normal cells. The mechanism of cell-speciﬁc delivery of
GNP to target tumor cells uses primary and secondary mono-
clonal antibodies for binding the GNP to cell membrane and
further cauterization of GNP into compact groups. In experi-
ments, we used human ALL and AML and normal bone marrow
samples to evaluate efﬁcacy and safety of LANTCET. Accumu-
lation of GNP in cells was studied with ﬂow cytometry, ﬂuo-
rescent microscopy, and electron microscopy. Using specially
developed incubation protocols for 30-nm GNP, we provided
controlled forming of GNP clusters in tumor cells only, while
only single GNP were discovered in normal stem cells due to
non-speciﬁc binding. After incubation with GNP, the cell sam-
ples were irradiated with single laser pulse (532 nm, 10 ns,
0.5–1.0 J/cm2). Cell damage levels were measured for tumor and
normal cells with ﬂow cytometry (necrosis and apoptosis). At
speciﬁc laser ﬂuence total damage of ALL cells and 84% of
AML cells was achieved while among normal cells only 16%
were damaged after single laser pulse. This method is now at the
stage of the development of an experimental system for purging
transplants (grafts) of bone marrow and blood.
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THE PLATELET COUNT AT INITIAL AUTOLOGOUS PERIPHERAL BLOOD
STEM CELL HARVEST DOES NOT INFLUENCE PLATELET ENGRAFTMENT
AFTER STEM CELL TRANSPLANTATION
Aljitawi, O.1, Merkel, D.1, Trieu, K.1, Deauna-Limayo, D.1,
Ganguly, S.1, Bodensteiner, D.1, Divine, C.1, Skikne, B.1 The Univer-
sity of Kansas Medical Center, Kansas City, KS.
Many factors inﬂuence marrow recovery after autologous pe-
ripheral blood stem cell (PBSC) transplantation. The status of
the patient’s bone marrow function at harvesting may certainly
be an important factor. This study was conducted to evaluate
whether the platelet count at the initial stem cell harvest pre-
dicts time to platelet and neutrophil engraftment after trans-
plantation. The data of 96 consecutive patients who underwent
autologous PBSC transplantation between 2001 and 2004 were
reviewed. Data collected included diagnosis, date of diagnosis,
date of ﬁrst harvest, number of harvests to obtain prerequisite
number of CD34 cells, platelet and neutrophil counts at initial
harvest, and time to platelet and neutrophil engraftment. An
adequate target CD34 cell number was 	2.5  106/kg patient
weight. The majority of patients had multiple myeloma (45%),
followed by non-Hodgkin’s lymphoma (25%), Hodgkin’s Dis-
ease (17%), and others (13%). Two collection groups were
identiﬁed, 1 group requiring only 1 collection period and a
second group requiring more than one. Seventy-one patients
required 1 collection period of up to 5 consecutive days of stem
cell harvest. The average harvest time to obtain the required
numbers of stem cells was 3.16 days. The average platelet count
at initial harvest was 187,000/uL. Average time to platelet en-
graftment was 19.2 days and to neutrophil engraftment was 11.6
days. Sixteen patients required 	1 peripheral stem cell collec-
tion periods. For these patients, the time to platelet engraftment
was 22.7 days and to neutrophil engraftment was 12.2 days.
Nine patients did not have platelet engraftment because they
either died before platelet engraftment or their platelets did not
engraft secondary to relapse of disease. The average initial count
of this group was 187,000/uL, similar to the other patient
group. There was no correlation between platelet count at ﬁrst
harvest and time to platelet engraftment (r  0.12141). Plate-
let engraftment time did not correlate with neutrophil engraft-
ment (r  0.1). In conclusion, patients who required 	1 pe-
ripheral stem cell collection period, have delayed engraftment of
platelets and to lesser extent delayed neutrophil engraftment,
when compared to patients requiring only one collection period.
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AUTOMATED SEPARATION OF CORD BLOOD MNC FRACTION IN A
CLOSED SYSTEM: THERMOGENESIS AXP SYSTEM
Dobrila, L.1, Jiang, S.1, Chapman, J.2, Marr, D.2, Kryston, K.2,
Rubinstein, P.1 1. National Cord Blood Program at New York Blood
Center, New York, NY; 2. ThermoGenesis Corp, Rancho Cordova, CA.
Background: Compliance with current good tissue practices
(cGTP) is essential to achieving product uniformity in cord blood
banks. A critical step in the processing of cord blood is volume
reduction, to allow standardization of the freezing rate and help
maintain stem cell viability and to optimize liquid nitrogen storage
space utilization. To enable instrumented cord blood volume re-
duction, ThermoGenesis developed the AutoXpress™ (AXP™)
System consisting of a microprocessor-controlled device and dis-
posable closed blood bag set. The AXP™ ﬁts standard refrigerated
blood bank centrifuge buckets. Cord blood is transferred to the bag
set and centrifuged. With the AXP™ system, up to 6 units of cord
blood can be processed at one time with a standard blood bank
centrifuge. Study Design: A study was performed to determine the
efﬁciency with which cord blood hematopoietic progenitor cells
can be recovered, using the CD34 cell marker and colony-forming
unit (CFU) counts as indices. Twenty-three consecutive cord
blood units were processed with the AXP™. The blood volume,
hematocrit, total nucleated cells (TNC), mononuclear cells
(MNC), CD34 cells, and colony-forming units were determined
in samples from cord blood units before and after AXP™ separa-
tion. Results: Results are presented as the mean  S.D. (N  23)
for all values. The AXP™ process achieved mononuclear (MNC)
fraction volumes of 19.7  0.3 ml with a ﬁnal average hematocrit
of 29.8  2.6%. The recovery was 98.2  8.0% (CD34 cells),
94.6  7.0% (CFU), 97.9  4.9% (MNC), and 84.8  9.2%
(TNC). Less than 1% of TNC were found in the excess plasma
bag. Fifteen percent of TNC were lost and recovered in the red cell
bag, and were mostly granulocytes. Less than 0.5% of the CD34
cells were found in the RBC bag. Conclusions: The AXP™ cord
blood volume reduction process automatically, efﬁciently, and re-
producibly separated cord blood mononuclear cells, CD34 cells,
and CFU activity. It achieved high recoveries (	94%) in a closed
system without requiring hetastarch. The volume target was de-
livered into the freezing bag with high precision. Thus, AXP™ can
meet the volume reduction quality standard for automated cord
blood processing.
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